Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial

(2015) G. Masi et al.   ANNALS OF ONCOLOGY

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

(2015) Paul Ruff et al.   EUROPEAN JOURNAL OF CANCER

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

(2014) Ian Chau et al.   BMC CANCER

Abstract B2: Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer.

(2014) M. Chiron et al.   MOLECULAR CANCER THERAPEUTICS

Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab’

(2013) F Bibeau et al.   BRITISH JOURNAL OF CANCER

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

(2013) F Loupakis et al.   BRITISH JOURNAL OF CANCER

Aflibercept

(2013) K. K. Ciombor et al.   CLINICAL CANCER RESEARCH

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

(2013) Josep Tabernero et al.   EUROPEAN JOURNAL OF CANCER

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

(2012) Nicholas Papadopoulos et al.   ANGIOGENESIS

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

(2012) H. J. Schmoll et al.   ANNALS OF ONCOLOGY

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

(2012) Jaafar Bennouna et al.   LANCET ONCOLOGY

Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study

(2012) J. C. Bendell et al.   ONCOLOGIST

Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration

(2011) F Fan et al.   BRITISH JOURNAL OF CANCER

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

(2010) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases

(2009) Yun Shin Chun   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set

(2008) Michael J. O'Connell et al.   JOURNAL OF CLINICAL ONCOLOGY